Literature DB >> 31061194

Rare case of a giant duodenal ulcer penetrating the pancreas during antiangiogenic treatment.

Carolina Palmela1, Catarina Gouveia1, Catarina Fidalgo1, Alexandre Oliveira Ferreira1.   

Abstract

We report a case of a patient with renal cell carcinoma on pazopanib, who presented with severe upper gastrointestinal bleeding. Endoscopy showed a giant bulbar ulcer with a visible vessel of 4 mm. Due to unavailability of surgical rescue backup, large calibre vessel treatment was delayed. Endoscopy was repeated after 48 hours and showed a reduction in the vessel diameter. Endoscopic adrenalin injection and electrocoagulation were performed. However, the vessel increased in size and became pulsatile. The patient was operated, confirming a giant bulbar ulcer penetrating the pancreas with active bleeding from the gastroduodenal artery. Pazopanib therapy was suspended, and the patient is asymptomatic. Antiangiogenic treatment has been associated with gastrointestinal bleeding, perforation and fistulisation. Although we cannot confirm the causal association between the penetrating ulcer and pazopanib, the absence of Helicobacter pylori infection or non-steroidal anti-inflammatory drugs, and the reported cases of gastrointestinal bleeding during these therapies favour a possible association. © BMJ Publishing Group Limited 2019. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  drugs: gastrointestinal system; endoscopy; stomach and duodenum; ulcer

Mesh:

Substances:

Year:  2019        PMID: 31061194      PMCID: PMC6510143          DOI: 10.1136/bcr-2018-228612

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  12 in total

1.  Effects of ketoconazole and esomeprazole on the pharmacokinetics of pazopanib in patients with solid tumors.

Authors:  Antoinette R Tan; Darlene G Gibbon; Mark N Stein; Diana Lindquist; Jeffery W Edenfield; Julie C Martin; Charles Gregory; A Benjamin Suttle; Hiroomi Tada; Jeffrey Botbyl; Joseph J Stephenson
Journal:  Cancer Chemother Pharmacol       Date:  2013-05-01       Impact factor: 3.333

2.  Late anastomotic colonic dehiscence due to antiangiogenic treatment, a specific drug-class complication requiring specific treatment: an example of pazopanib complication.

Authors:  Clarisse Eveno; Christine le Maignan; Philippe Soyer; Marine Camus; Emmanuel Barranger; Marc Pocard
Journal:  Clin Res Hepatol Gastroenterol       Date:  2011-02       Impact factor: 2.947

3.  Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial.

Authors:  Martin E Gore; Cezary Szczylik; Camillo Porta; Sergio Bracarda; Georg A Bjarnason; Stéphane Oudard; Subramanian Hariharan; Se-Hoon Lee; John Haanen; Daniel Castellano; Eduard Vrdoljak; Patrick Schöffski; Paul Mainwaring; Alejandra Nieto; Jinyu Yuan; Ronald Bukowski
Journal:  Lancet Oncol       Date:  2009-07-15       Impact factor: 41.316

4.  Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study.

Authors:  E Van Cutsem; F Rivera; S Berry; A Kretzschmar; M Michael; M DiBartolomeo; M-A Mazier; J-L Canon; V Georgoulias; M Peeters; J Bridgewater; D Cunningham
Journal:  Ann Oncol       Date:  2009-04-30       Impact factor: 32.976

Review 5.  Role of angiogenesis in tumor growth and metastasis.

Authors:  Judah Folkman
Journal:  Semin Oncol       Date:  2002-12       Impact factor: 4.929

Review 6.  Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis.

Authors:  Sanjaykumar Hapani; David Chu; Shenhong Wu
Journal:  Lancet Oncol       Date:  2009-06       Impact factor: 41.316

Review 7.  Metastatic renal cell carcinoma: many treatment options, one patient.

Authors:  Brian I Rini
Journal:  J Clin Oncol       Date:  2009-05-26       Impact factor: 44.544

8.  Effect of Concomitant pH-Elevating Medications with Pazopanib on Progression-Free Survival and Overall Survival in Patients with Metastatic Renal Cell Carcinoma.

Authors:  Renee K McAlister; Jonathan Aston; Megan Pollack; Liping Du; Tatsuki Koyama; David D Chism
Journal:  Oncologist       Date:  2018-02-27

9.  Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer.

Authors:  Fairooz Kabbinavar; Herbert I Hurwitz; Louis Fehrenbacher; Neal J Meropol; William F Novotny; Grazyna Lieberman; Susan Griffing; Emily Bergsland
Journal:  J Clin Oncol       Date:  2003-01-01       Impact factor: 44.544

Review 10.  Mechanisms of adverse effects of anti-VEGF therapy for cancer.

Authors:  T Kamba; D M McDonald
Journal:  Br J Cancer       Date:  2007-05-22       Impact factor: 7.640

View more
  1 in total

1.  Obstructive Jaundice Due to Duodenal Ulcer Induced by Lenvatinib Therapy for Hepatocellular Carcinoma.

Authors:  Maito Suoh; Atsushi Hagihara; Masafumi Yamamura; Hirotsugu Maruyama; Koichi Taira; Masaru Enomoto; Akihiro Tamori; Yasuhiro Fujiwara; Norifumi Kawada
Journal:  Intern Med       Date:  2020-10-07       Impact factor: 1.271

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.